Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Dunlop

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 22, 2015
The Suitability of End Point Designs for Health Technology Assessment in Chronic Pain StudiesCatherine E Rycroft, Matthew Hirst, William C N Dunlop, et al.
Journal of Medical Economics|August 27, 2016
A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the futureSimone Critchlow, Matthew Hirst, Ron Akehurst, et al.
AIDS Research and Human Retroviruses|March 1, 1996
Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunizationJ D Ahlers, N Dunlop, C D Pendleton, et al.
Journal of Medical Genetics|May 23, 1998
Organisation of the human PAX4 gene and its exclusion as a candidate for the Wolcott-Rallison syndromeD T Bonthron, N Dunlop, D G Barr, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1993
Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizationsJ D Ahlers, C D Pendleton, N Dunlop, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 24, 2015
Estimating the health care burden of prescription opioid abuse in five European countriesAmie Shei, Matthew Hirst, Noam Y Kirson, et al.
Developments in Biological Standardization|January 1, 1990
Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selectionP Nara, L Smit, N Dunlop, et al.
Pharmacoeconomics|July 6, 2016
BEACON: A Summary Framework to Overcome Potential Reimbursement HurdlesWilliam C N Dunlop, C Daniel Mullins, Olaf Pirk, et al.
British Journal of Cancer|March 26, 1998
Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenouslyD I Jodrell, A Bowman, M Stewart, et al.
Immunopharmacology|September 21, 2000
The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokinesB Q Li, T Fu, W H Gong, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 22, 2015
The Suitability of End Point Designs for Health Technology Assessment in Chronic Pain StudiesCatherine E Rycroft, Matthew Hirst, William C N Dunlop, et al.
Journal of Medical Economics|August 27, 2016
A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the futureSimone Critchlow, Matthew Hirst, Ron Akehurst, et al.
AIDS Research and Human Retroviruses|March 1, 1996
Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunizationJ D Ahlers, N Dunlop, C D Pendleton, et al.
Journal of Medical Genetics|May 23, 1998
Organisation of the human PAX4 gene and its exclusion as a candidate for the Wolcott-Rallison syndromeD T Bonthron, N Dunlop, D G Barr, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1993
Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizationsJ D Ahlers, C D Pendleton, N Dunlop, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 24, 2015
Estimating the health care burden of prescription opioid abuse in five European countriesAmie Shei, Matthew Hirst, Noam Y Kirson, et al.
Developments in Biological Standardization|January 1, 1990
Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selectionP Nara, L Smit, N Dunlop, et al.
Pharmacoeconomics|July 6, 2016
BEACON: A Summary Framework to Overcome Potential Reimbursement HurdlesWilliam C N Dunlop, C Daniel Mullins, Olaf Pirk, et al.
British Journal of Cancer|March 26, 1998
Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenouslyD I Jodrell, A Bowman, M Stewart, et al.
Immunopharmacology|September 21, 2000
The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokinesB Q Li, T Fu, W H Gong, et al.
Pageof 4